Advertisement


Elizabeth A. Mittendorf, MD, PhD, on Immunotherapy in Breast Cancer: Expert Perspective

2017 San Antonio Breast Cancer Symposium

Advertisement

Elizabeth A. Mittendorf, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses the growing role of immunotherapy in treating breast disease, the evidence of biomarkers that may be associated with response to therapy, and the opportunities to perform robust correlative studies.



Related Videos

Breast Cancer

Debu Tripathy, MD, on HR+, HER2– Breast Cancer: Results From the MONALEESA-7 Trial

Debu Tripathy, MD, of The University of Texas MD Anderson Cancer Center, discusses phase III study findings on first-line ribociclib vs placebo with goserelin and tamoxifen or a nonsteroidal aromatase inhibitor in premenopausal women with hormone receptor–positive, HER2-negative advanced breast cancer (Abstract GS2-05).

Breast Cancer

Eric S. Winer, MD, on Metastatic Breast Cancer: Debate on a Research Tool

Eric S. Winer, MD, of the Dana-Farber Cancer Institute, addresses the much-discussed controversy over whether all women diagnosed with metastatic breast cancer should undergo next-generation sequencing.

Breast Cancer

Joseph A. Sparano, MD, on Stage II–III Breast Cancer and CTCs

Joseph A. Sparano, MD, of Montefiore Medical Center/Albert Einstein College of Medicine, discusses findings that suggest circulating tumor cells 5 years after diagnosis are prognostic for late recurrence in operable stage II–III breast cancer (Abstract GS6-03).

Breast Cancer

Wolfgang Janni, MD, PhD, on Early Breast Cancer and Bisphosphonate Treatment: Results From the SUCCESS A Trial

Wolfgang Janni, MD, PhD, of Ulm University, discusses study findings that showed extended adjuvant bisphosphonate treatment over 5 years in early breast cancer does not improve disease-free and overall survival when compared with 2 years of treatment (Abstract GS1-06).

Breast Cancer

Matteo Lambertini, MD, on Preserving Fertility in Patients With Early Breast Cancer: Pooled Analysis

Matteo Lambertini, MD, of the Institut Jules Bordet, discusses the results of five clinical trials investigating temporary ovarian suppression with gonadotropin-releasing hormone analogs during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal early breast cancer patients (Abstract GS4-01).

Advertisement

Advertisement




Advertisement